VAR - Varian receives Investigational Device Exemption for clinical trial of FLASH therapy

Varian (VAR) has received an Investigational Device Exemption (‘IDE’) from the Food and Drug Administration for the first-ever clinical trial of FLASH therapy.FLASH therapy, involving ultra-high dose rates, and delivery in typically less than one second, may be over 100 times faster compared to conventional radiation therapy.The study, named FAST-01 (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases), will involve the investigational use of Varian's ProBeam particle accelerator modified to offer this advanced non-invasive treatment option for patients with cancer.Varian anticipates enrollment of the first patient in the FAST-01 Feasibility Study by the end of 2020."Preclinical research of FLASH therapy indicates using ultra-high dose rates may be less toxic overall and enhance sparing of adjacent healthy tissue," commented Deepak "Dee" Khuntia, M.D., Senior Vice President and Chief Medical Officer of Varian.

For further details see:

Varian receives Investigational Device Exemption for clinical trial of FLASH therapy